Compare Medpace Holdings Inc (MEDP) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Western Alliance Bancorporation — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Western Alliance Bancorporation trades at $81.03 (market cap $8.84B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.07% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | WAL | |
|---|---|---|
Market Cap | $15.08B | $8.84B |
Sector | Technology | Financials |
52-Week High | $620.59 | $96.08 |
52-Week Low | $308.88 | $66.70 |
Enterprise Value | $14.55B | — |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with a Q2 2026 EPS estimate of $2.33. Strong profitability is evident with a net income margin of 25.63% and ROE of 13.47%, while valuation ratios like a P/E of 9.58 suggest potential undervaluation. Recent news highlights operational achievements, including being named Arizona's #1 bank by Forbes in June 2026.
The outlook for WAL is positive, supported by analyst consensus with 79% buy ratings and a $90.67 price target, implying ~12% upside. Investment opportunities include earnings growth and sector leadership, but risks involve negative operating cash flow in 2025 and high interest expenses of $1.83B that could pressure margins if rates rise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
